Two small pilot studies have indicated that targeting GM-CSF in patients with severe COVID-19 lung diseases using anti–GM-CSF receptor monoclonal antibodies mavrilimumab or lenzilumab, respectively, may be a strategy for improving clinical outcomes (3, 4), although larger controlled clinical trials would be needed to determine efficacy and biological impact of such approaches. Here, CSF2 is linked to lung disorder.